MGMT and glioblastoma: Many FDA‐approved drugs have been considered for drug repurposing for their autophagy‐modulating and antitumor properties.[441] For instance, chlorpromazine was found to trigger cytotoxic autophagy in glioblastoma cells through ER stress and is currently being evaluated in clinical trials for GBM patients with hypo‐ or unmethylated MGMT gene, which have intrinsic resistance to temozolomide.[442] Repurposed drugs have a known safety/toxicity profile, may benefit from reduced cost and development time, and offer improved access to patients.